![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fiercepharma.com/special-report/top-10-antibody-drug-conjugate-contenders-2021
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761060
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761060
http://www.pmlive.com/pharma_news/nice_set_to_reject_pfizers_leukaemia_drug_besponsa_1202669
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761040
http://www.fiercebiotech.com/biotech/fda-accepts-pfizer-s-blood-cancer-candidate-for-speedy-review
http://press.pfizer.com/press-release/pfizer-announces-acceptance-regulatory-submission-inotuzumab-ozogamicin-us-food-and-dr
http://www.forbes.com/sites/elaineschattner/2016/12/05/inotuzumab-ozogamicin-a-new-kind-of-antibody-treatment-for-b-cell-acute-lymphocytic-leukemia/#631d88653e01
http://www.outsourcing-pharma.com/Preclinical-Research/Pfizer-hits-up-four-biotechs-in-46m-R-D-collaboration-strategy
http://www.prnewswire.com/news-releases/celator-pharmaceuticals-announces-participation-in-cardiff-university-clinical-trial-in-adults-with-acute-myeloid-leukemia-or-high-risk-myelodysplastic-syndrome-aml19-300202001.html